**Arcus Biosciences Reports Financial Results and Strategic Updates in Annual Filing**
Arcus Biosciences, Inc., a late clinical-stage biopharmaceutical company, filed its 10-K report, outlining its financial performance and key operational developments for the fiscal year ending December 31, 2025. The company, focused on developing differentiated molecules for cancer and inflammatory diseases, reported a net loss of $353 million for 2025, compared to a net loss of $283 million in 2024. This increase in net loss is attributed to higher research and development expenditures, partially offset by increased revenue from collaborations. Total revenue for 2025 was $247 million, a decrease of 4% compared to $258 million in 2024, primarily due to lower revenue from the Taiho collaboration and the Gilead collaboration, partially offset by a higher cumulative catch-up to revenue under the Gilead Collaboration.
The company's research and development expenses increased by 17% to $523 million in 2025, up from $448 million in 2024. This rise reflects increased enrollment and clinical activities in Phase 3 studies for casdatifan and quemliclustat, partially offset by lower costs for domvanalimab Phase 3 studies. General and administrative expenses decreased by 8% to $110 million in 2025, compared to $120 million in 2024, primarily driven by decreases in compensation and personnel costs. As of December 31, 2025, Arcus Biosciences held $1.0 billion in cash, cash equivalents, and marketable securities.
Operationally, Arcus Biosciences highlighted the discontinuation of the Phase 3 STAR-221 clinical trial for domvanalimab due to futility, while other Phase 3 studies for domvanalimab remain ongoing. The company also completed enrollment in the Phase 3 PRISM-1 study for quemliclustat in metastatic pancreatic cancer, with results expected in the first half of 2027. Additionally, Taiho exercised its option for an exclusive license to casdatifan in Japan and certain other Asian territories. The company's workforce comprised 601 full-time employees as of December 31, 2025, with approximately 81% engaged in research and development activities.
Looking ahead, Arcus Biosciences anticipates initiating a Phase 3 clinical trial for casdatifan in a TKI-free regimen for first-line ccRCC by the end of 2026. The company also expects to advance its first development candidate from its inflammation and autoimmune disease programs into the clinic in 2026. A futility analysis is expected to be conducted for the STAR-121 study in the first quarter of 2026. The company believes its current cash reserves will be sufficient to fund operations until at least the second half of 2028.
About Arcus Biosciences, Inc.
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing novel immuno-oncology therapies for cancer treatment. Its portfolio includes small molecules and antibodies targeting immune checkpoints and cancer cell pathways, such as TIGIT, PD-1, and adenosine receptors. Arcus focuses on combination therapies for lung, gastrointestinal, renal, and other cancers, collaborating with partners like Gilead for development and commercialization, while leveraging third-party manufacturing and strategic licensing.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.